Flot.bio x Philip Hemme
by Flot.bio
Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free.Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.
Episodes
-
Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63
Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners before joining Angelini Ventures in 2025. The corporate venture fund now manages close to €500M, and its first exit, Noctrix Health, sold to ResMed for $340M in June.We talked about Forbion, Jeito and…
more -
MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a...
-
Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61
Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress of AtaiBeckley, and why he thinks ‘going home…
more -
ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60
After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025. In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology space, including highlights from ASCO 2026, ADCs…
more -
CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]
Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise investments.Jean‑François tells us how the exit unfolded, as well as the importance of biosafety and CMC as pharma and biotech outsource...
-
Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58
When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping $5 billion. We talk about the bureaucracy of Big Pharma, rare diseases, and why a biotech M&A supercycle isn’t as…
more -
Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57
We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio candidate Forward Therapeutics in Phase I.We also talk about major bottom-up...
-
Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56
Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences investments in Europe via the Life Sciences VC Coalition. We chat about building European biotech champions like Argenx,...
-
Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]
Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines. We discuss how Immunethep could challenge Pfizer’s $7bn+ Prevnar, and how one pharma company got on board after a…
more -
António Portela, Bial 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54
We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned. We cover Bial’s pipeline, including treatments for epilepsy and Parkinson’s, and why Bial’s multigenerational leadership story is nowhere as…
more -
Claus Crone Fuglsang, Novonesis 🇩🇰 | Biosolutions, Industrial biotech, Synbio | E53
Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up. ⭐️ ABOUT THE SPEAKER Claus first…
more -
Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored]
At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing...
-
Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis, Long-Acting Injections | E51
Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breathe new life into generic drugs, making it easier for patients to stick to…
more -
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50
Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China. --- Learn more about Transgene: https://bit.ly/tg_flotbio...
-
Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49
Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting. The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first...
-
Werner Lanthaler 🇦🇹 | Biopharma AI, CDMO, Antibody Optimization | E48
Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sabbatical in 2024. We talk about his new missions as FairJourney CEO and…
more -
Thomas Lingelbach, Valneva | Vaccines, Lyme Disease | E47
Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry. ⭐️ ABOUT THE SPEAKER A…
more -
Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46
When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround. Marc discusses the processes involved in…
more -
Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45
As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership…
more -
Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored]
As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing. Philip sits down with co-founder Gerrit...
-
Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43
We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui. Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of...
-
Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored]
Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of...
-
Dragan Grabulovski, Araris 🇨🇭 | ADC Linkers, Replacing Chemotherapy | E41
Philip meets up with Dragan Grabulovski, CEO of the startup Araris, at Lake Zurich to chat about the company’s work with antibody-drug conjugates (ADCs).They talk about Araris’ huge $400M upfront buyout by Taiho Pharma of Japan, Dragan’s extensive history as a biotech entrepreneur, and Araris’...
-
Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40
On a trip to Basel, Switzerland, Philip catches up with Stefano Portolano, CEO of the European firm Azafaros. They chat about Azafaros’ massive $147M Series B round in May 2025, which is being used to develop a small molecule treatment for rare diseases known as lysosomal storage…
more -
Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39
We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine. Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year. Alex gives us a tour of Insilico’s sprawling pipeline, a...
-
Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38
We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer. The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A...
-
Aino Kalervo, TILT Biotherapeutics 🇫🇮 | Immunotherapy, Oncolytic Virus | E37 [Sponsored]
We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its...
-
Renee Aguiar-Lucander, Hansa Biopharma 🇸🇪 | Immunology, Gene therapy | E36
Fresh after leading Calliditas Therapeutics through a $1.1B acquisition, Renee Aguiar-Lucander takes us through her new CEO role at Hansa Biopharma 🇸🇪.We learn how Hansa is commercialising Idefirix, its lead product for improving outcomes in kidney transplantation. We also cover the hot area of...
-
Stephane Bancel, Moderna | mRNA Therapeutics, Boston Biotech Mafia, AI Biotech | E35
We’re with Stephane Bancel, CEO of the US mRNA giant Moderna. The company’s 15-year trajectory has taken it from the startup seed stage to a commercial heavyweight with three mRNA-based products in the market 🧬 We go in-depth into Stephane’s leadership style and background before delving into...
-
Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34
We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of...
-
Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 [Sponsored]
We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This...
-
Joris Pezzini, Alira Health | Hottest Biotech Insights | E32 [Sponsored]
We’re in Barcelona 🇪🇸 with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs. --- This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more...
-
Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31
We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries. ⭐️ ABOUT THE...
-
Christoph Broja, EQT 🇩🇪🇳🇱 | #1 European Biotech VC, LSP Marriage, ADCs | E30
We’re in Munich 🇩🇪 with Cristoph Broja, Partner at EQT Life Sciences, the top venture capital firm in Europe.We talk about his lessons up until becoming a partner at the firm. We also talk about how to invest in hot areas such as obesity or ADCs, and the importance of being curious. ⭐️ ABOUT…
more -
Philipp Baaske, NanoTemper 🇩🇪 | Bootstrapping in Biotech | E29 [Sponsored]
We’re in Munich with Philipp Baaske, one of the best life science tool founders in Europe. We talked about the lessons of building this life science tools business, specialized in protein interactions. We also talked about the difficulties and rewards of entrepreneurship and the impact of life...
-
Mathias Uhlen 🇸🇪 | Entrepreneurial Scientist, 26 times | E28
We’re online 🇸🇪 with Mathias Uhlen, one of the best entrepreneurial scientists in Europe. We talked about the entrepreneurial mindset in academia. We also talked about AI for biology and why he doesn’t believe in the current anti-ageing drugs. ⭐️ ABOUT THE SPEAKER Looking at the career of…
more -
Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27
We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos. We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully. ⭐️ ABOUT THE SPEAKER At just…
more -
Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26
We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's. We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma...
-
Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25
We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years. We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China. ⭐️ ABOUT THE SPEAKER Sean joined BioNTech in 2012 as part of the…
more -
Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24
In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the...
-
Szabolcs Nagy, Turbine 🇭🇺 | AI in Biotech, Simulation | E23 [Sponsored]
We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world.We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from…
more -
Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and…
more -
Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21
We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier.We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career.⭐️ ABOUT THE SPEAKERMarina was recommended...
-
Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based Therapeutics | E20
We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh.We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in...
-
Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19
We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a…
more -
Otello Stampacchia, Omega Funds 🇮🇹 | M&A, Boston & Pasta | E18
We’re in Boston 🇺🇸 with one of the top VCs, Otello Stampacchia of Omega Funds. We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago. 💎...
-
Christina Takke, V-Bio Ventures 🇧🇪 | Wonder VC Woman | E17
We’re in San Sebastián 🇪🇸 with one of the top VCs in Europe, Christina Takke from V-Bio Ventures. We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three...
-
Naveed Siddiqi, Novo Holdings 🇬🇧🇩🇰 | Sharp Macro View of EU Biotech | E16
We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity.…
more -
Claudia Ulbrich, Cardior 🇩🇪 | Being the Founder of a Rare €1B Exit | E15
We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”. 💎 ABOUT THE SPEAKER Claudia has been founding biotechs since…
more -
Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14
We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a...
About this show
Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free.Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.
Hosted by
Flot.bio